Structural analysis and evaluation of the 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) gene in human essential hypertension

Journal of Hypertension

Volumn 16, Issue 11, 1998, Pages 1627-1633

  Brand, Eva ^a   Kato, Norihiro ^b   Chatelain, Nathalie ^a   Krozowski, Zygmunt S ^c   Jeunemaitre, Xavier ^d   Corvol, Pierre ^d   Plouin, Pierre François ^e   Cambien, François ^f   Pascoe, Leigh ^d,g   Soubrier, Florent ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d PSL Research University   (France)

^e HÔPITAL BROUSSAIS   (France)

^f INSERM   (France)

^g FONDATION JEAN DAUSSET CEPH   (France)

Author keywords

11 hydroxysteroid dehydrogenase type 2; Association study; Bi allelic polymorphism; Essential hypertension; Linkage study; Microsatellite marker

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; DNA; MICROSATELLITE DNA;

ADULT; AGED; ALLELE; AMINO ACID SEQUENCE; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; COSMID VECTOR; ESSENTIAL HYPERTENSION; EXON; FAMILY HISTORY; FRANCE; GENE MUTATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN VARIANT; SIBLING; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL ANALYSIS;

EID: 15144343124     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816110-00009     Document Type: Article

References (35)

1. White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med 1994; 15:421-438.
2. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237:268-275.
3. Monder C, White PC. 11β-hydroxysteroid dehydrogenase. Vitam Horm 1993; 47:187-271.
4. Stewart PM, Murry BA, Mason JI. Human kidney 11β-hydroxysteroid dehydrogenase is a high affinity NAD-dependent enzyme and differs from the cloned type 1 isoform. J Clin Endocrinol Metab 1994; 79:480-484.
5. Edwards CRW, Stewart PM, Burt D, Bretl L, McIntyre MA, Sutanto WS, et al. Localisation of 11β-hydroxysteroid dehydrogenase: tissue specific protector of the mineralocorticoid receptor. Lancet 1988; ii:986-989.
6. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242:583-585.
7. Brown RW, Chapman KE, Edwards CRW, Seckl JR. Human placental 11β-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD+-dependent isoform Endocrinology 1993; 132:2614-2621.
8. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105:R11-R17.
9. Naray-Fejes-Toth A. Expression cloning of the aldosterone target cell-specific 11 beta-hydroxysteroid dehydrogenase from rabbit collecting duct cells. Endocrinology 1995; 136:2579-2586.
10. Agarwal AK, Rogerson FM, Mune T, White PC. Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11β-hydroxysteroid dehydrogenase. Genomics 1995; 29:195-199.
11. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of Cortisol. J Clin Endocrinol Metab 1979; 49:757-764.
12. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996; 347:88-91.
13. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat Genet 1995; 10:394-399.
14. Elston RC. Genetic analysis workshop II: sib pair screening tests for linkage. Genet Epidemiol 1984; 1:175-178.
15. Haseman JK, Elston RC. The investigation of linkage between a quantitative trait and a marker locus. Behav Genet 1972; 2:3-19.
16. SAGE: statistical analysis for genetic epidemiology, release 2.2. SIBPAL version 2.5. New Orleans: Department of Biometry and Genetics, LSU Medical Centre; 1994.
17. Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh K, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996; 14:199-202.
18. Brand E, Chatelain N, Keavney B, Caulfield M, Citterio L, Connell J, et al. Evaluation of the angiotensinogen locus in human essential hypertension: a european study. Hypertension 1998; 31:725-729.
19. Tiret L, Blanc H, Ruidavets J-B, Arveiler D, Luc G, Jeunemaitre X, et al. Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study. J Hypertens 1998; 16:37-44.
20. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5:874-879.
21. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, Stone EM. The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 1993; 16:325-332.
22. Saiki RK. Genetic analysis of enzymatically amplified β-globin and HLA-DQA genomic DNA with allele specific oligonucleotide probes. Nature 1986; 324:163-166.
23. Jeunemaitre X, Soubrier F, Kotelevtsev Y, Lifton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71:169-180.
24. Bonnardeaux A, Davies E, Jeunemaitre X, Féry I, Charru A, Clauser E, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994; 24:63-69.
25. Julier C, Delepine M, Keavney B, Terwilliger J, Davies S, Weeks DE, et al. Genetic susceptibility for human familial essential hypertension in a region of homology with blood pressure linkage on rat chromosome 10. Hum Mol Genet 1997; 6:2077-2085.
26. Law CM, de Swiet M, Osmond C, Fayers PM, Barker DJP, Cruddas AM, et al. Initiation of hypertension in utero and its amplification throughout life. BMJ 1993; 306:24-27.
27. Barker DJP, Bull AR, Osmond CO, Simmonds SJ. Fetal and placental size and risk of hypertension in adult life. BMJ 1990; 301:259-262.
28. Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retard intrauterine growth. Science 1978; 202:436-438.
29. Lindsay RS, Lindsay RM, Edwards CRW, Seckl JR. Inhibition of 11β-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. Hypertension 1996; 27:1200-1204.
30. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CRW. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 1993; 341:339-341.
31. Edwards CRW, Benediktsson R, Lindsay RS, Seckl JR. Dysfunction of placental glucocorticoid barrier: link between foetal environment and adult hypertension? Lancet 1993; 341:355-357.
32. Barker DJP. Fetal origins of coronary heart disease. BMJ 1995; 311:171-174.
33. Watson B, Bergmann SM, Myracle A, Callen DF, Acton RT, Warnock DG. Genetic association of 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension 1996; 28:478-482.
34. Smolenicka Z, Bach E, Schaer A, Liechti-Gallati S, Frey BM, Frey FJ, et al. A new polymorphic restriction site in the human 11β-hydroxysteroid dehydrogenase type 2 gene. J Clin Endocrinol Metab 1998; 83:1814-1817.
35. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273:1516-1517.